Fig. 1

Pancancer genomic alteration landscape, expression pattern, prognostic significance, and immunological correlation of the thymosin family. A The location of TMSs on 23 chromosomes. B Landscape of genomic aberrations in the TMSs in cancer. Each row represents a gene, and each column represents a patient. Only patients with genomic alterations in the indicated genes are shown. Alteration rates per TMS gene are displayed on the left. C Distribution of (up) mutation and (middle and down) CNA frequencies over cancer types. The darkness of color is proportional to the frequency. D Differential expression of TMS genes in 19 different cancer types. FC and p values were obtained by comparing normal tissue with the corresponding tumor tissue. Color is displayed only when P value < 0.05. Red indicates upregulation, while blue indicates downregulation. E Summary of Cox regression correlation of TMSs with survival. Color is displayed only when P value < 0.05. Red indicates worse survival. F Correlation between TMSB10 expression and (up) immune score, as well as (down) stromal score, across 33 cancer types. G Differences in the TMSs between six different immune molecular subtypes. The Kruskal–Wallis test was used to determine the significance of differences between the six immune molecular subtypes. H Box plot showing the distribution of sample-specific pathway scores across 33 cancer types. The median, interquartile range, and outliers are indicated. I The expression of TMSB10 between GTEx normal tissues and tumor tissues. The statistical significance is indicated as follows: ns > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001